Trade Report: Top 10 Cannabis-Based Neurology Innovators in 2025
As cannabinoid-based pharmaceuticals move from fringe therapy to mainstream treatment, a new class of biopharmaceutical innovators is capturing attention from regulators, clinicians, and investors alike. From neurological disorders like refractory epilepsy to inflammation and pain management, cannabis-derived therapies—especially those high in cannabidiol (CBD) and low in tetrahydrocannabinol (THC)—are redefining global drug markets. This report provides […]
Cannabis and Epilepsy: Scientific Evidence, Clinical Trials, and Market Impact of High-CBD Therapies
Cannabis-based medicine has entered the scientific and regulatory mainstream, with epilepsy at the forefront of its therapeutic promise. High-CBD, low-THC cannabis formulations are now recognized as legitimate, evidence-backed options for patients with treatment-resistant epilepsy. This report dives into the clinical validation of these therapies, major product milestones such as Epidiolex, and the global regulatory and […]
The Rise of Decentralized Clinical Trials: What It Means for Innovation
Clinical trials have long been the engine of medical innovation — but they have also been notoriously slow, expensive, and exclusive. Now, decentralized clinical trials (DCTs) are emerging as a transformative solution, reshaping how research is conducted and who gets to participate.Driven by technological advances and accelerated by the COVID-19 pandemic, DCTs are unlocking faster, […]
Clinical Trial Success Rates: How Data Is Changing the Game
Clinical trials have always been the heartbeat of medical innovation—but they’re also notoriously risky, expensive, and time-consuming. For decades, investors, researchers, and pharmaceutical companies have operated under the sobering reality that most clinical trials fail. In fact, only around 9–14% of drugs that enter Phase I ever make it to market. But 2025 marks a […]